{"slideshow_credits": null, "snippet": "The story behind the approval of Procysbi, a new treatment, is an example of the important role that determined parents and disease foundations can play in supporting drug development.", "abstract": "Food and Drug Administration approves drug Procysbi to treat nephropathic cystinosis, extremely rare inherited disease that, if untreated, typically destroys the kidneys by age 10; to be sold by Raptor Pharmaceutical Corp, drug was developed with early financing from a foundation that shows the important role that determined parents can play in drug development, but also raises questions about whether society can afford to pay for drugs that treat rare illnesses.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/05/01/business/fda-approves-raptor-drug-for-form-of-cystinosis.html", "lead_paragraph": "The story behind the approval of Procysbi, a new treatment, is an example of the important role that determined parents and disease foundations can play in supporting drug development.", "headline": {"seo": "F.D.A. Approves Raptor Drug for Form of Cystinosis", "main": "Parental Quest Bears Fruit in a Kidney Disease Treatment", "print_headline": "A Rare Ailment and a High Price"}, "_id": "51811cd8cf28d006f1000118", "word_count": "1446", "multimedia": [{"height": 126, "url": "images/2013/05/01/business/01drug/01drug-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/05/01/business/01drug/01drug-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 387, "url": "images/2013/05/01/business/01drug/01drug-articleLarge.jpg", "legacy": {"xlarge": "images/2013/05/01/business/01drug/01drug-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "387"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/05/01/business/01drug/01drug-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/05/01/business/01drug/01drug-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-05-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Kidneys", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Raptor Pharmaceutical Corp", "name": "organizations", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}